IPM Take
The policy signal is that Alzheimer’s care is moving beyond memory decline alone. Agitation is one of the symptoms that pushes families toward crisis, emergency care and institutionalisation, yet it has often been managed with limited treatment options and heavy caregiver burden. A new approved option matters, but access will depend on whether dementia pathways can identify agitation properly, support caregivers and monitor treatment safely in real-world settings.
Executive Summary
On 30 April 2026, FDA approved an expanded use for Auvelity, dextromethorphan hydrobromide and bupropion hydrochloride extended-release tablets, to treat agitation associated with dementia due to Alzheimer’s disease in adults. FDA described Auvelity as the first FDA-approved treatment for this condition that is not an antipsychotic and noted that it had initially been approved in 2022 for major depressive disorder in adults. The updated FDA label states that Auvelity is indicated for agitation associated with dementia due to Alzheimer’s disease, but is not indicated as an as-needed treatment for agitation.
Why it matters
- Regulators: This approval expands the treatment landscape for Alzheimer’s-related agitation and adds a non-antipsychotic option to an area with high clinical and caregiver burden.
- Clinicians: Need to distinguish agitation associated with Alzheimer’s dementia from other causes of behavioural change and monitor blood pressure, seizure risk, drug interactions and tolerability.
- Patients / advocates: Should watch whether the new option is embedded in broader dementia support, not used as a substitute for caregiver support, environmental management and appropriate follow-up.
Before this approval, Alzheimer’s drug policy was dominated by disease-modifying therapies, biomarker pathways and debates around anti-amyloid access. But for families and care systems, behavioural symptoms such as agitation can be just as disruptive.
What has changed is that Auvelity now has a specific FDA-approved indication for agitation associated with dementia due to Alzheimer’s disease in adults. This is not a general dementia indication, not a treatment for all behavioural symptoms and not an as-needed medicine for occasional agitation.
The eligible population is adults with agitation associated with dementia due to Alzheimer’s disease. That makes diagnosis and context important. Agitation may reflect pain, infection, medication effects, environmental stress, delirium, depression, caregiver strain or progression of dementia, so prescribing needs to sit inside a proper assessment pathway.
The implementation question is practical. Clinicians need clear diagnosis, medication review, caregiver input and monitoring for safety and tolerability. For IPM, the lesson is that personalised dementia care cannot focus only on amyloid biology. It must also address the symptoms that determine whether patients can remain safely supported at home.
